The Risks Of Investing In GlaxoSmithKline Plc

Royston Wild outlines the perils of stashing your cash in GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am highlighting what you need to know before investing in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Chinese walls closing in

Needless to say, one of the biggest challenges facing GlaxoSmithKline is what the ongoing corruption investigation in China is likely to mean for future earnings. With two corporate investigators, who allege to have been hired by the pharma giant to investigate bribery lGlaxoSmithKlineeaks in the country, about to be put in the dock for charges of illegally purchasing and selling information, China is clearly prepared to drag the company through the mud.

The waters have been muddied further by news that three former employees of GlaxoSmithKline’s Chinese division are suing the firm for illegal dismissal. The plaintiffs are also claiming reimbursement for unpaid expenses used to bribe medical staff and which were signed off by company management, Reuters reported.

The division’s former head, Mark Reilly, is accused by state prosecutors of overseeing a ‘massive bribery network‘ and is currently detained along with two other high-level executives. Sales in the country have headed through the floor as a consequence, and with more twists likely to emerge in this long-running saga, huge questions remain over GlaxoSmithKline’s future in this mammoth marketplace.

Health plans play hardball

The pharmaceuticals sector’s big players have seen earnings take a significant dent in recent years, as the loss of exclusivity across a number of high-profile earnings drivers has enabled generic substitutes to take a chunk out of their market share.

But the likes of GlaxoSmithKline are also being put on the back foot by many healthcare scheme operators, who are becoming more reluctant to shell out a premium to acquire certain treatments in the light of rising bills, a move which threatens to drive the sector into a bloody price war.

As The New York Times reported last month, Express Scripts — by far the biggest Pharmacy Benefit Manager (PBM) in the US, entities whose remit includes processing and settling prescription drug benefits — has stopped paying for GlaxoSmithKline’s Advair respiratory product as well as a number of other high-profile labels.

Advair alone currently accounts for a fifth of GlaxoSmithKline’s revenues, and with many generic firms tipped to introduce their cheaper alternatives from 2016, the Brentford-firm’s top line could be set for severe turbulence in coming years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »